Tempus Acquires Paige to Enhance Digital Pathology Capabilities
Tempus has announced the acquisition of Paige.AI, a leader in digital pathology, for $81.25 million, as stated in a press release. This acquisition allows Tempus to expand its dataset and technical team, strengthening its position in digital pathology with Paige's industry-leading technology portfolio.
Founded in 2017, Paige has developed several AI applications, including the first FDA-cleared AI application in pathology, which aids in cancer detection. Paige's proprietary dataset includes nearly 7 million digitized pathology slides, providing a robust foundation for advancing cancer research and drug development.
The acquisition is expected to accelerate Tempus's efforts in building a comprehensive foundation model in oncology, leveraging Paige's extensive dataset and expertise in generative AI. The transaction is primarily financed through Tempus common stock, along with the assumption of Paige's existing commitments under its Microsoft Azure cloud services agreement.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Funding
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more